Personalized immune cells target aggressive lymphoma in groundbreaking trial
NCT ID NCT03590574
Summary
This study tested a personalized cell therapy called AUTO4 for patients with T-cell non-Hodgkin lymphoma that had returned or didn't respond to previous treatments. Doctors collected patients' own immune cells, engineered them in a lab to better target cancer, and then infused them back into the body. The main goals were to check if the treatment was safe and to see if it could shrink or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
-
Manchester Royal Infirmary Hospital
Manchester, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, United Kingdom
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.